FIELD: medicine; pharmaceutics.
SUBSTANCE: treatment of muscular atrophy. The use of kynurenic acid for the treatment of muscular atrophy, which is presarcopenia, sarcopenia, or severe sarcopenia.
EFFECT: effective treatment of muscular atrophy.
5 cl, 8 dwg, 1 tbl, 4 ex
| Title | Year | Author | Number |
|---|---|---|---|
| DERIVATIVES USED FOR TREATING MUSCULAR ATROPHY | 2016 |
|
RU2715553C2 |
| APPLICATION OF ANGIOGENIN OR ANGIOGENIN AGONISTS FOR TREATING DISEASES AND DISORDERS | 2009 |
|
RU2519645C2 |
| CHEMICAL COMPOUNDS AND USE THEREOF TO IMPROVE QUALITY OF MUSCLES | 2015 |
|
RU2724329C2 |
| USE OF MYOSTATIN ANTAGONISTS, COMBINATION CONTAINING THEM AND THEIR USE | 2016 |
|
RU2781401C2 |
| IMPROVED ANTIBODIES GDF-8 ANTAGONISTS AND THEIR USE | 2013 |
|
RU2630634C2 |
| NOVEL HYBRID ACTRIIB LIGAND TRAP PROTEINS FOR TREATING DISEASES ASSOCIATED WITH MUSCULAR ATROPHY | 2016 |
|
RU2733492C2 |
| COMPOSITIONS AND METHODS FOR IMPROVED MUSCULAR METABOLISM | 2016 |
|
RU2730853C2 |
| COMPOSITIONS CONTAINING NICOTINE AMIDRIBOSIDE AND UROLITIN | 2016 |
|
RU2751638C2 |
| MYOSTATIN SIGNAL INHIBITOR | 2019 |
|
RU2820270C2 |
| AGONISTS OF CORTICOTROPIN-RELEASING FACTOR RECEPTOR | 2003 |
|
RU2286995C2 |
